SHTDY (Sinopharm Group Co) Issuance of Debt: $15,163 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHTDY Sinopharm Group Co Ltd SHTDY
69 GF Score
Price $11.21
GF Value $13.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Issuance of Debt?

Sinopharm Group Co SHTDY -1.41% 69 Issuance of Debt is $15,163 Mil as of Dec. 2025. GuruFocus rates SHTDY with a GF Score™ of 69/100 and a GF Value™ of $13.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sinopharm Group Co's Issuance of Debt for the six months ended in Dec. 2025 was $6,581 Mil.

Sinopharm Group Co's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was $15,163 Mil.

Sinopharm Group Co Issuance of Debt Related Terms

Sinopharm Group Co Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Issuance of Debt Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,688.02 15,269.00 14,906.88 14,686.20 15,330.21

Sinopharm Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,270.09 8,750.92 5,966.53 8,582.51 6,580.51
SHTDY
69GF Score
Sinopharm Group Co Ltd SHTDY
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $15,163 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $15,163 Mil mean?
Sinopharm Group Co (SHTDY) has a Issuance of Debt of $15,163 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Issuance of Debt too high?
Sinopharm Group Co's current Issuance of Debt is $15,163 Mil. Overall, Sinopharm Group Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Issuance of Debt compare to MCK and CAH?
Sinopharm Group Co's Issuance of Debt of $15,163 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Medical Distribution company?
A good Issuance of Debt depends on the Medical Distribution industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Issuance of Debt is $15,163 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.31, compared to a current price of $11.21 — trading 15.8% below its estimated fair value. The current Issuance of Debt is $15,163 Mil. Sinopharm Group Co's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Issuance of Debt is $15,163 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDY) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $11.21 is trading 15.8% below its estimated GF Value™ of $13.31. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDY:

  • Issuance of Debt: $15,163 Mil
  • GF Value™: $13.31 vs. price of $11.21 (15.8% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
69GF Score

Get the complete analysis for SHTDY

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.21
Price
$13.31
GF Value